新城發展(01030.HK):1月至11月累計合同銷售2129.67億元
格隆匯12月1日丨新城發展(01030.HK)發佈公吿,2021年11月,集團實現合約銷售金額約人民幣200.56億元;合約銷售面積約213.33萬平方米。2021年1月至11月累計合同銷售金額約人民幣2,129.67億元;累計銷售面積約2,096.32萬平方米。
土地收購方面,公司通過招拍掛方式取得山東省日照市編號為2021A-54號地塊。該地塊位於日照市興海路以南、東關南路以東,出讓面積為1,343.17平方米,規劃用途為商業用地,容積率為≤2.5,計容建築面積約為3,357.93平方米。集團需支付土地價款人民幣570.00萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.